Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2024

Open Access 01-12-2024 | Keloid | Study protocol

A randomised clinical trial study assessing the efficacy of 5% losartan potassium loaded in ethosomal gel to treat human keloids: a trial protocol

Authors: Yuni Eka Anggraini, Niken Trisnowati, Ronny Martien, Retno Danarti

Published in: Trials | Issue 1/2024

Login to get access

Abstract

Background

Keloid is a skin disorder that results from excessive fibrous tissue growth in the area of the initial trauma. Treating keloids can be challenging since the success of various treatments varies from one study to another. Triamcinolone acetonide injection, a standard treatment, can cause undesirable side effects. Meanwhile, the effectiveness of existing topical therapies for keloids is not always reliable. The pro-inflammatory, pro-proliferative, and pro-fibrotic effects of angiotensin II in human skin contribute to keloid formation. Losartan potassium, an angiotensin II blocker, has the potential to act as an anti-keloid agent. Due to the thicker skin structure of a keloid and ease of application, ethosome gel is chosen as a safe and comfortable carrier for losartan potassium, making it a good choice for treating keloids.

Methods

In this randomised clinical trial, 46 adults with keloids were divided into two treatment groups. One group of 23 participants received 5% losartan potassium loaded in ethosomal gel, while the other group of 23 participants received intralesional injections of 10% triamcinolone acetonide. Over 12 weeks, changes in POSAS 3.0 scores, degree of erythema and pigmentation, surface area, thickness, and pliability of the keloids will be measured at four different times: baseline, 4 weeks, 8 weeks, and 12 weeks. Statistical analysis will be conducted using SPSS software version 24, with a significance level of p < 0.05.

Discussion

Losartan potassium is believed to be beneficial for keloid management because it inhibits the angiotensin II receptor, which plays a role in inflammation, proliferation, and fibrosis. This study examines the efficacy of 5% losartan potassium loaded in ethosomal gel for human keloids.

Trial registration

Clinicaltrial.gov identifier NCT05893108. Registered on 7 June 2023.
Literature
1.
Dinulos JGH. Keloid and hypertrophic scars. In: Habif’s Clinical Dermatology. 7th ed. Elsevier Inc.; 2021. p. 799–801.
2.
Bock O, Schmid-Ott G, Malewski P, Mrowietz U. Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res. 2006;297(10):433–8.PubMedCrossRef
3.
Zhang X, Liu Y, Deng X, Deng C, Pan Y, Hu A. The correlation between quality of life and acceptability of disability in patients with facial burn scars. Front Bioeng Biotechnol. 2019;7:1–7.CrossRef
4.
Elsaie ML. Update on management of keloid and hypertrophic scars: a systemic review. J Cosmet Dermatol. 2021;20(9):2729–38.PubMedCrossRef
5.
Berman B, Maderal A, Raphael B. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. Dermatol Surg. 2017;43:S3–18.PubMedCrossRef
6.
Wang ZC, Zhao WY, Cao Y, Liu YQ, Sun Q, Shi P, et al. The roles of inflammation in keloid and hypertrophic scars. Front Immunol. 2020;11:1–10.
7.
Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med. 2011;17(1–2):113–25.PubMedCrossRef
8.
Steckelings UM, Czarnelzki BM. The renin-angiotensin-system in the skin: evidence for its presence and possible functional implications. Exp Dermatol. 1995;4(6):329–34.PubMedCrossRef
9.
Steckelings UM, Wollschläger T, Peters J, Henz BM, Hermes B, Artuc M. Human skin: source of and target organ for angiotensin II. Exp Dermatol. 2004;13(3):148–54.PubMedCrossRef
10.
Yahata Y, Shirakata Y, Tokumaru S, Yang L, Dai X, Tohyama M, et al. A novel function of angiotensin II in skin wound healing: induction of fibroblast and keratinocyte migration by angiotensin II via heparin-binding epidermal growth factor (EGF)-like growth factor-mediated EGF receptor transactivation. J Biol Chem. 2006;281(19):13209–16.PubMedCrossRef
11.
Akershoek JJ, Vlig M, Brouwer K, Talhout W, Beelen RHJ, Middelkoop E, et al. The presence of tissue renin-angiotensin system components in human burn wounds and scars. Burn Open. 2018;2(3):114–21.CrossRef
12.
Niazi F, Hooshyar SH, Hedayatyanfard K, Ziai SA, Doroodgar F, Niazi S, et al. Detection of angiotensin II and AT1 receptor concentrations in keloid and hypertrophic scar. J Clin Aesthet Dermatol. 2018;11(10):36–9.PubMedPubMedCentral
13.
Silva IMS, Assersen KB, Willadsen NN, Jepsen J, Artuc M, Steckelings UM. The role of the renin-angiotensin system in skin physiology and pathophysiology. Exp Dermatol. 2020;29:891–901.PubMedCrossRef
14.
Hedayatyanfard K, Haddadi N, Ziai SA, Karim H, Niazi F, Steckelings UM, et al. The renin-angiotensin system in cutaneous hypertrophic scar and keloid formation. Exp Dermatol. 2020;29(9):902–9.PubMedCrossRef
15.
Nor NM, Ismail R, Jamil A, Shah SA, Imran FH. A randomized, single-blind trial of clobetasol propionate 0.05% cream under silicone dressing occlusion versus intra-lesional triamcinolone for treatment of keloid. Clin Drug Investig. 2017;37(3):295–301.PubMedCrossRef
16.
Mustoe TA, Cooter RD, Gold MH, Hobbs FDR, Ramelet AA, Shakespeare PG, et al. International clinical recommendations on scar management. Plastic Reconstruct Surg. 2002;110:560–71.CrossRef
17.
Limmer EE, Glass DA. A review of current keloid management: mainstay monotherapies and emerging approaches. Dermatol Ther (Heidelb). 2020;10(5):931–48.PubMedCrossRef
18.
Coppola MM, Salzillo R, Segreto F, Persichetti P. Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives. Clin Cosmet Investig Dermatol. 2018;11:387–96.CrossRef
19.
Zhuang ZH, Li YT, Wei XJ. The safety and efficacy of intralesional triamcinolone acetonide for keloids and hypertrophic scars: a systematic review and meta-analysis. Burns. 2021;47(5):987–98.PubMedCrossRef
20.
Berman B, Flores F. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections. J Am Acad Dermatol. 1997;37(5 I):755–7.PubMedCrossRef
21.
McLenon J, Rogers MA. The fear of needles: A systematic review and meta‐analysis. J Adv Nurs. 2019;75(1):30–42.
22.
Sidgwick GP, McGeorge D, Bayat A. A comprehensive evidence-based review on the role of topicals and dressings in the management of skin scarring. Arch Dermatol Res. 2015;307(6):461–77.PubMedPubMedCentralCrossRef
23.
Morrow D, McCarron P, Woolfson A, Donnely R. Innovative strategies for enhancing topical and transdermal drug delivery. Open Drug Deliv J. 2007;1:36–59.CrossRef
24.
25.
Ardekani GS, Aghaie S, Nemati MH, Handjani F, Kasraee B. Treatment of a postburn keloid scar with topical captopril: report of the first case. Plast Reconst Surg. 2009;123(3):112e–3e.
26.
Demir CY, Ersoz ME, Erten R, Kocak OF, Sultanoglu Y, Basbugan Y. Comparison of enalapril, candesartan and intralesional triamcinolone in reducing hypertrophic scar development: an experimental study. Aesthetic Plast Surg. 2018;42(2):352–61.PubMedCrossRef
27.
Zheng B, Fang QQ, Wang XF, Shi BH, Zhao WY, Chen CY, Zhang MX, Zhang LY, Hu YY, Shi P, Ma L. The effect of topical ramipril and losartan cream in inhibiting scar formation. Biomed & Pharmacother. 2019;118:109394.
28.
Rha EY, Kim JW, Kim JH, Yoo G. Angiotensin-converting enzyme inhibitor, captopril, improves scar healing in hypertensive rats. Int J Med Sci. 2021;18(4):975–83.PubMedPubMedCentralCrossRef
29.
Hedayatyanfard K, Ziai SA, Niazi F, Habibi I, Habibi B, Moravvej H. Losartan ointment relieves hypertrophic scars and keloid: a pilot study. Wound Repair Regen. 2018;26(4):340–3.PubMedCrossRef
30.
Mohammadi AA, Parand A, Kardeh S, Janati M, Mohammadi S. Efficacy of topical enalapril in treatment of hypertrophic scars. World J Plast Surg. 2018;7(3):326–31.PubMedPubMedCentralCrossRef
31.
Khodaei B, Nasimi M, Nassireslami E, Seyedpour S, Rahmati J, Haddady Abianeh S, et al. Efficacy of topical losartan in management of mammoplasty and abdominoplasty scars: a randomized, double-blind clinical trial. Aesthetic Plast Surg. 2022;46(5):2580–7.PubMedCrossRef
32.
Limandjaja GC, Belien JM, Scheper RJ, Niessen FB, Gibbs S. A study looking at the differences between hypertrophic scars and keloid scars. Br J Dermatol. 2020;182(4):18219.CrossRef
33.
Huang C, Wu Z, Du Y, Ogawa R. The epidemiology of keloids. Textbook on scar management: state of the art management and emerging technologies. 2020:29–35.
34.
Patil P, Datir S, Saudagar R. A review on topical gels as drug delivery system. J Drug Deliv Ther. 2019;9(3):661–8.
35.
Zsikó S, Csányi E, Kovács A, Budai-Szűcs M, Gácsi A, Berkó S. Methods to evaluate skin penetration in vitro. Scientia Pharmaceutica. 2019;87(3):1–21.
36.
Zhang Z, Chen J, Huang J, Wo Y, Zhang Y, Chen X. Experimental study of 5-fluorouracil encapsulated ethosomes combined with CO2 fractional laser to treat hypertrophic scar. Nanoscale Res lett. 2018;13:1–12.
37.
Kunii T, Hirao T, Kikuchi K, Tagami H. Stratum corneum lipid profile and maturation pattern of corneocytes in the outermost layer of fresh scars: the presence of immature corneocytes plays a much more important role in the barrier dysfunction than do changes in intercellular lipids. Br J Dermatol. 2003;149(4):749–56.PubMedCrossRef
38.
Limandjaja GC, van den Broek LJ, Waaijman T, van Veen HA, Everts V, Monstrey S, et al. Increased epidermal thickness and abnormal epidermal differentiation in keloid scars. Br J Dermatol. 2017;176(1):116–26.PubMedCrossRef
39.
Nandura HP, Prashant Puranik PG, Lone V. Ethosome: a novel drug carrier. Pharm Sci. 2013;2(3):18–30.
40.
Zhang Z, Tsai PC, Ramezanli T, Michniak-Kohn BB. Polymeric nanoparticles-based topical delivery systems for the treatment of dermatological diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013;5(3):205–18.PubMedPubMedCentralCrossRef
41.
Natsheh H, Touitou E. Phospholipid vesicles for dermal/transdermal and nasal administration of active molecules: The effect of surfactants and alcohols on the fluidity of their lipid bilayers and penetration enhancement properties. Molecules. 2020;25(13):1–42.
42.
Paolino D, Lucania G, Mardente D, Alhaique F, Fresta M. Ethosomes for skin delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers. J Control Release. 2005;106(1–2):99–110.PubMedCrossRef
43.
Madsen JT, Vogel S, Karlberg AT, Simonsson C, Johansen JD, Andersen KE. Ethosome formulation of contact allergens may enhance patch test reactions in patients. Contact Dermatitis. 2010;63(4):209–14.PubMedCrossRef
44.
Madsen JT, Vogel S, Karlberg AT, Simonsson C, Johansen JD, Andersen KE. Ethosome formulations of known contact allergens can increase their sensitizing capacity. Acta Derm Venereol. 2010;90(4):374–8.PubMedCrossRef
45.
Madsen JT, Vogel S, Johansen JD, Sørensen JA, Andersen KE, Nielsen JB. Percutaneous penetration characteristics and release kinetics of contact allergens encapsulated in ethosomes. Cutan Ocul Toxicol. 2011;30(1):38–44.PubMedCrossRef
46.
Madsen JT, Vogel S, Johansen JD, Andersen KE. Encapsulating contact allergens in liposomes, ethosomes, and polycaprolactone may affect their sensitizing properties. Cutan Ocul Toxicol. 2011;30(2):116–23.PubMedCrossRef
47.
Sguizzato M, Esposito E, Cortesi R. Lipid-based nanosystems as a tool to overcome skin barrier. Int J Mol Sci. 2021;22(15):1–16.CrossRef
48.
Bhana R, Verma A, Jain S. Development and characterization of ethosomes bearing losartan potassium for transdermal drug delivery. Int J Pharm Pharm Sci. 2013;5(1):35–40.
49.
Chung JH. The effects of sunlight on the skin of Asians. In 2001. p. 69–90.
50.
Zlowodzki M, Bhandari M. Outcome measures and implications for sample-size calculations. J Bone Jt Surg. 2009;91(SUPPL. 3):35–40.CrossRef
51.
52.
53.
54.
Dahlan MS. Statistik Untuk Kedokteran Dan Kesehatan. 4th ed. Jakarta: Salemba Medika 2009. p. 27.
55.
Dahlan MS. Komparatif-Kategorik-Tidak Berpasangan Lebih dari Satu Kali Pengukuran. In: Besar Sampel dalam Penelitian Kedokteran dan Kesehatan. 5th ed. Jakarta: Epidemiologi Indonesia; 2020. p. 124–31.
56.
57.
Draaijers LJ, Tempelman FRH, Botman YAM, Tuinebreijer WE, Middelkoop E, Kreis RW, et al. The Patient and Observer Scar Assessment Scale: a reliable and feasible tool for scar evaluation. Plast Reconstr Surg. 2004;113(7):1960–5.PubMedCrossRef
58.
Verhaegen PDHM, Van Der Wal MBA, Middelkoop E, Van Zuijlen PPM. Objective scar assessment tools: a clinimetric appraisal. Plast Reconstr Surg. 2011;127(4):1561–70.PubMedCrossRef
59.
Van Der Wal M, Bloemen M, Verhaegen P, Tuinebreijer W, De Vet H, Van Zuijlen P, et al. Objective color measurements: clinimetric performance of three devices on normal skin and scar tissue. J Burn Care Res. 2013;34(3):187–94.CrossRef
60.
Kim MS, Rodney WN, Cooper T, Kite C, Reece GP, Markey MK. Towards quantifying the aesthetic outcomes of breast cancer treatment: comparison of clinical photography and colorimetry. J Eval Clin Pract. 2009;15(1):20–31.PubMedPubMedCentralCrossRef
61.
62.
van Zuijlen PPM, Angeles AP, Suijker MH, Kreis RW, Middelkoop E. Reliability and accuracy of techniques for surface area measurements of wounds and scars. Int J Low Extrem Wounds. 2004;3(1):7–11.PubMedCrossRef
63.
Witmer WK, Lebovitz PJ. Clinical photography in the dermatology practice. Semin Cutan Med Surg. 2012;31(3):191–9.PubMedCrossRef
64.
Aragón-Sánchez J, Quintana-Marrero Y, Aragón-Hernández C, Hernández-Herero MJ. ImageJ: a free, easy, and reliable method to measure leg ulcers using digital pictures. Int J Low Extrem Wounds. 2017;16(4):269–73.PubMedCrossRef
65.
Bessonart MN, Macedo N, Carmona C. High resolution B-scan ultrasound of hypertrophic scars. Ski Res Technol. 2005;11(3):185–8.CrossRef
66.
Lee KC, Dretzke J, Grover L, Logan A, Moiemen N. A systematic review of objective burn scar measurements. Burns Trauma. 2016;4:1–33.
67.
Reinholz M, Schwaiger H, Poetschke J, Epple A, Ruzicka T, Von Braunmühl T, et al. Objective and subjective treatment evaluation of scars using optical coherence tomography, sonography, photography, and standardised questionnaires. Eur J Dermatol. 2016;26(6):599–608.PubMedCrossRef
68.
Poetschke J, Schwaiger H, Gauglitz GG. Current and emerging options for documenting scars and evaluating therapeutic progress. Dermatol Surg. 2017;43:S25–36.PubMedCrossRef
69.
Lye I, Edgar DW, Wood FM, Carroll S. Tissue tonometry is a simple, objective measure for pliability of burn scar: is it reliable? J Burn Care Res. 2006;27(1):82–5.PubMedCrossRef
70.
de Oliveira GV, de Morais Gambogi Alvarenga LR, de Oliveira Duarte Stuhr PM, Cantaruti TA, Ferreira ÁRS, Kitten GT. Treatment of median sternotomy scars using triamcinolone injections, silicone dressings and a combination group: a prospective randomized comparative study. Surg Cosmet Dermatol. 2020;12(1):34–41.
71.
Dolynchuk KN, Tredget EE. A Preliminary report of the biochemical and clinical effects of 1,4-diaminobutane on prevention of human hypertrophic scars. Plast Reconstr Surg. 2020;145(1):76e–84e.PubMedCrossRef
72.
Zhao T, Zhao W, Meng W, Liu C, Chen Y, Sun Y. Vascular endothelial growth factor-C: its unrevealed role in fibrogenesis. Am J Physiol Hear Circ Physiol. 2014;306(6):789–96.CrossRef
73.
Fang QQ, Wang XF, Zhao WY, Chen CY, Zhang MX, Shi BH, et al. The source of ACE during scar formation is from both bone marrow and skin tissue. FASEB J. 2018;32(9):5199–208.PubMedCrossRef
74.
Pereira RM, Dos Santos RAS, Dias FLDC, Teixeira MM, Simões e Silva AC. Renin-angiotensin system in the pathogenesis of liver fibrosis. World J Gastroenterol. 2009;15(21):2579–86.PubMedPubMedCentralCrossRef
75.
Ren M, Hao S, Yang C, Zhu P, Chen L, Lin D, et al. Angiotensin II regulates collagen metabolism through modulating tissue inhibitor of metalloproteinase-1 in diabetic skin tissues. Diabetes Vasc Dis Res. 2013;10(5):426–35.CrossRef
76.
Colwell AS, Phan TT, Kong W, Longaker MT, Lorenz PH. Hypertrophic scar fibroblasts have increased connective tissue growth factor expression after transforming growth factor-β stimulation. Plast Reconstr Surg. 2005;116(5):1387–90.PubMedCrossRef
77.
78.
Kovács MG, Kovács ZZ, Varga Z, Szűcs G, Freiwan M, Farkas K, Kővári B, Cserni G, Kriston A, Kovács F, Horváth P. Investigation of the Antihypertrophic and antifibrotic effects of losartan in a rat model of radiation-induced heart disease. Int J Mol Sci. 2021;22(23):1–24.
79.
Insel PA, Murray F, Yokoyama U, Romano S, Yun H, Brown L, et al. CAMP and Epac in the regulation of tissue fibrosis. Br J Pharmacol. 2012;166(2):447–56.PubMedPubMedCentralCrossRef
80.
Yeh FL, Der SH, Lin MW, Chang CY, Tai HY, Huang MH. Keloid-derived fibroblasts have a diminished capacity to produce prostaglandin E2. Burns. 2006;32(3):299–304.PubMedCrossRef
81.
Sandulache VC, Parekh A, Li-Korotky H, Dohar JE, Hebda PA. Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-β1-induced collagen synthesis. Wound Repair Regen. 2007;15(1):122–33.PubMedCrossRef
82.
Zhao J, Shu B, Chen L, Tang J, Zhang L, Xie J, et al. Prostaglandin E2 inhibits collagen synthesis in dermal fibroblasts and prevents hypertrophic scar formation in vivo. Exp Dermatol. 2016;25(8):604–10.PubMedCrossRef
83.
Molina-Molina M, Serrano-Mollar A, Bulbena O, Fernandez-Zabalegui L, Closa D, Marin-Arguedas A, et al. Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis. Thorax. 2006;61(7):604–10.PubMedPubMedCentralCrossRef
84.
Mbah CC, Builders PF, Attama AA. Nanovesicular carriers as alternative drug delivery systems: ethosomes in focus. Expert Opin Drug Deliv. 2014;11(1):45–59.PubMedCrossRef
85.
Gabrijelčič V, Šentjurc M. Influence of hydrogels on liposome stability and on the transport of liposome entrapped substances into the skin. Int J Pharm. 1995;118(2):207–12.CrossRef
Metadata
Title
A randomised clinical trial study assessing the efficacy of 5% losartan potassium loaded in ethosomal gel to treat human keloids: a trial protocol
Authors
Yuni Eka Anggraini
Niken Trisnowati
Ronny Martien
Retno Danarti
Publication date
01-12-2024
Publisher
BioMed Central
Keywords
Keloid
Losartan
Published in
Trials / Issue 1/2024
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-023-07880-2

Other articles of this Issue 1/2024

Trials 1/2024 Go to the issue

Study protocol

Statistical analysis plan for the multicenter, open, randomized controlled clinical trial to assess the efficacy and safety of intravenous tirofiban vs aspirin in acute ischemic stroke due to tandem lesion, undergoing recanalization therapy by endovascular treatment (ATILA trial)

Study protocol

Gamma oscillations induced by 40-Hz visual-auditory stimulation for the treatment of acute-phase limb motor rehabilitation after stroke: study protocol for a prospective randomized controlled trial

Study protocol

Lifestyle intervention in children with obesity and nonalcoholic fatty liver disease (NAFLD): study protocol for a randomized controlled trial in Ningbo city (the SCIENT study)

Study protocol

Nutritional treatment of children 6–59 months with severely low weight-for-age z-score: a study protocol for a 3-arm randomized controlled trial

Study protocol

Total laparoscopic partial hepatectomy versus open partial hepatectomy for primary left-sided hepatolithiasis: study protocol for a randomized controlled trial

Study protocol

Study protocol: a core outcome set for perioperative exercise clinical effectiveness trials for lung cancer patients